Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
5
83%
Ph phase_3
1
17%

Phase Distribution

5

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting4
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (83.3%)
Phase 31 (16.7%)

Trials by Status

recruiting467%
completed233%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_3

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598
recruitingphase_1

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

NCT07227025
recruitingphase_1

A Study of Olomorasib (LY3537982) in Healthy Participants

NCT07439250
completedphase_1

A Study of Olomorasib (LY3537982) in Healthy Japanese Participants

NCT07124013
recruitingphase_1

A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants

NCT07044271
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06890598Phase 3

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
NCT07227025Phase 1

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

Recruiting
NCT07439250Phase 1

A Study of Olomorasib (LY3537982) in Healthy Participants

Recruiting
NCT07124013Phase 1

A Study of Olomorasib (LY3537982) in Healthy Japanese Participants

Completed
NCT07044271Phase 1

A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants

Recruiting
NCT06719128Phase 1

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6